Physician profile
Danny Lin
NPI 1871595710
$16,817.56
in general payments reported to CMS, 2019-2025
28 companies · $489 in 2025
The $489 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $820 · 2020: $156 · 2021: $159 · 2022: $13K · 2023: $1,016 · 2024: $882 · 2025: $489.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,885 · Long Term Medical Supply Or Device Loan: $501.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,885.11 |
| Long Term Medical Supply Or Device Loan | $501.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $12,024.06 | 2022-2024 | Rxsight Injector Cartridge, Rxsight Contact Lens, Light Adjustable Lens (Lal) |
| Carl Zeiss Meditec USA, INC. | $1,437.97 | 2022-2023 | Lumera, Lumera 700 |
| Alcon Vision LLC | $1,234.45 | 2019-2025 | Clareon, Rocklatan, Clareon Panoptix Pro |
| Abbvie INC. | $812.55 | 2022-2025 | |
| Carl Zeiss Meditec, INC. | $178.13 | 2019 | |
| Omeros Corporation | $173.94 | 2019 | |
| Astellas Pharma US INC | $103.00 | 2023-2024 | Izervay |
| Sight Sciences, INC. | $89.81 | 2021-2024 | Omni Surgical System, Sion Surgical Instrument |
| Novartis Pharmaceuticals Corporation | $80.51 | 2020-2023 | |
| Apellis Pharmaceuticals, INC. | $71.03 | 2022-2024 | Syfovre |
| Aerie Pharmaceuticals, INC. | $67.40 | 2019 | |
| Bausch & Lomb Americas INC. | $67.14 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Amgen INC. | $54.12 | 2024-2025 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $53.65 | 2019-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $53.04 | 2022-2023 | Tecnis Iol, Tecnis Iol |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $47.39 | 2019 | |
| Hologic Sales and Service, LLC | $39.79 | 2024 | Aptima |
| Biotissue Holdings INC. | $24.10 | 2023 | |
| Oyster Point Pharma, INC. | $23.45 | 2023 | Tyrvaya |
| Kala Pharmaceuticals, INC. | $22.82 | 2021 | |
| Thea Pharma INC. | $22.75 | 2024 | Iyuzeh |
| Horizon Therapeutics Plc | $22.67 | 2023 | Tepezza |
| Dompe US, INC. | $22.61 | 2024 | Oxervate |
| Allergan, INC. | $20.88 | 2021 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Genentech USA, INC. | $19.18 | 2024 | Vabysmo |
| Tarsus Pharmaceuticals, INC. | $16.22 | 2024 | Xdemvy |
| Shire North American Group INC | $15.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danny Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.